Literature DB >> 23007276

Assessment of maximum weight change and duration of therapeutic effect for non-surgical treatment of obesity using an exponential model.

E M Kaptein1, L S Chan, J S Kaptein.   

Abstract

Efficacy of weight loss and maintenance therapies in obesity is difficult to quantify due to continuous weight changes over time. We assessed a single exponential model of weight changes during selected non-surgical therapies of non-diabetic obese subjects. We analyzed published mean weight data from 6 studies of ≥12 weeks duration, with comparable treatment groups, and ≥4 weight measurements during very low carbohydrate or fat diets, or treatment with Lorcaserin, Sibutramine or Orlistat. We fit data to a single exponential model to estimate maximum predicted weight loss or regain and duration of weight loss or regain for each therapy. A single exponential is the appropriate model as determined by Kolmogorov-Smirnov, constant variance, and Durbin-Watson tests. Validity of parameter estimates was indicated by coefficients of variation <25%. Sensitivity analysis showed that weight regain at the end of the weight loss phase affected parameter estimates in some instances, with variations of weight loss of 0.2-0.7% of basal. Estimated weight loss and regain were similar to observed weight changes in all studies. The model could also be used to assess dose-response relationships. Estimates from the model were used to compare concurrent obesity regimens using 95% confidence intervals, taking into account pre-determined minimal clinically important differences. This exponential model may provide accurate estimates of maximum achievable weight loss or regain and optimal duration of efficacy for a variety of non-surgical weight loss and maintenance regimens from published mean weight data and may be useful to more accurately evaluate weight loss and maintenance regimens.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23007276     DOI: 10.3275/8631

Source DB:  PubMed          Journal:  Eat Weight Disord        ISSN: 1124-4909            Impact factor:   4.652


  25 in total

1.  Reporting weight loss: is simple better?

Authors:  Arya M Sharma; Shahzeer Karmali; Daniel W Birch
Journal:  Obesity (Silver Spring)       Date:  2010-02       Impact factor: 5.002

Review 2.  Voluntary weight loss: systematic review of early phase body composition changes.

Authors:  S B Heymsfield; D Thomas; A M Nguyen; J Z Peng; C Martin; W Shen; B Strauss; A Bosy-Westphal; M J Muller
Journal:  Obes Rev       Date:  2011-05       Impact factor: 9.213

3.  A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy women.

Authors:  Bonnie J Brehm; Randy J Seeley; Stephen R Daniels; David A D'Alessio
Journal:  J Clin Endocrinol Metab       Date:  2003-04       Impact factor: 5.958

4.  A 2-year multifactor approach of weight loss maintenance.

Authors:  V Makoundou; E Bobbioni-Harsch; J-P Gachoud; F Habicht; Z Pataky; A Golay
Journal:  Eat Weight Disord       Date:  2010 Mar-Jun       Impact factor: 4.652

5.  Meta-analysis: pharmacologic treatment of obesity.

Authors:  Zhaoping Li; Margaret Maglione; Wenli Tu; Walter Mojica; David Arterburn; Lisa R Shugarman; Lara Hilton; Marika Suttorp; Vanessa Solomon; Paul G Shekelle; Sally C Morton
Journal:  Ann Intern Med       Date:  2005-04-05       Impact factor: 25.391

6.  Sibutramine produces dose-related weight loss.

Authors:  G A Bray; G L Blackburn; J M Ferguson; F L Greenway; A K Jain; C M Mendel; J Mendels; D H Ryan; S L Schwartz; M L Scheinbaum; T B Seaton
Journal:  Obes Res       Date:  1999-03

7.  Prevalence of overweight and obesity in the United States, 1999-2004.

Authors:  Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal
Journal:  JAMA       Date:  2006-04-05       Impact factor: 56.272

8.  One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.

Authors:  N Finer; W P James; P G Kopelman; M E Lean; G Williams
Journal:  Int J Obes Relat Metab Disord       Date:  2000-03

Review 9.  Thyroid hormone therapy for obesity and nonthyroidal illnesses: a systematic review.

Authors:  Elaine M Kaptein; Elizabeth Beale; Linda S Chan
Journal:  J Clin Endocrinol Metab       Date:  2009-09-08       Impact factor: 5.958

10.  Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.

Authors:  M H Davidson; J Hauptman; M DiGirolamo; J P Foreyt; C H Halsted; D Heber; D C Heimburger; C P Lucas; D C Robbins; J Chung; S B Heymsfield
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.